AstraZeneca

The initial FDA approval of Thermo Fisher's NGS panel test for personalizing cancer treatment may allow rapid expansion to new indications.

The so-called universal CDx approved by the FDA can gauge alterations across multiple genes associated with response to three lung cancer treatments. 

AstraZeneca will use Trovagene's Trovera EGFR urine liquid biopsy test in an open-label prospective biomarker study.

In head-to-head studies, a next-generation EGFR inhibitor and an ALK inhibitor beat their older counterparts in staving of cancer progression.  

The first randomized study to show a PARP inhibitor benefits advanced breast cancer patients is also a sign of the expanding utility of BRCA testing in precision medicine.

The AstraZeneca Centre for Genomics Research has tapped DNAnexus to develop a secure genomics informatics environment for analyzing 2 million genomes.

The companies aim to develop a genomic test to differentiate respiratory allergens from irritants to help with drug discovery.

The company signed separate agreements with AstraZeneca, Merck, Merck KGaA, and Pfizer to create the panel, which is expected to help speed drug development.

The molecular diagnostics firm said it will submit its BRACAnalysis CDx alongside AstraZeneca's Lynparza to Japan's Pharmaceuticals and Medical Devices Agency.



The update includes several key initiatives such as a liquid biopsy database, a DoD-led longitudinal study, and NCI cloud collaborations with Amazon and Microsoft.

Pages

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.